Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Expression of the bric-a-brac tramtrack broad complex protein NAC-1 in cervical carcinomas seems to correlate with poorer prognosis.

Yeasmin S, Nakayama K, Ishibashi M, Katagiri A, Iida K, Purwana IN, Nakayama N, Miyazaki K.

Clin Cancer Res. 2008 Mar 15;14(6):1686-91. doi: 10.1158/1078-0432.CCR-07-4085.

2.

Biological and clinical significance of NAC1 expression in cervical carcinomas: a comparative study between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas.

Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Iida K, Nakayama N, Otuski Y, Kobayashi H, Nakayama S, Miyazaki K.

Hum Pathol. 2012 Apr;43(4):506-19. doi: 10.1016/j.humpath.2011.05.021. Epub 2011 Sep 1.

PMID:
21889186
3.

Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes.

Yeasmin S, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Iida K, Otsuki Y, Kobayashi H, Nakayama S, Miyazaki K.

Gynecol Oncol. 2010 Jun;117(3):409-16. doi: 10.1016/j.ygyno.2010.03.004. Epub 2010 Mar 31.

PMID:
20359736
4.

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.

Iida K, Nakayama K, Rahman MT, Rahman M, Ishikawa M, Katagiri A, Yeasmin S, Otsuki Y, Kobayashi H, Nakayama S, Miyazaki K.

Br J Cancer. 2011 Jul 26;105(3):420-7. doi: 10.1038/bjc.2011.222. Epub 2011 Jul 5.

5.

A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.

Ishibashi M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Fukumoto M, Miyazaki K.

Clin Cancer Res. 2008 May 15;14(10):3149-55. doi: 10.1158/1078-0432.CCR-07-4358.

6.

Tumor hypoxia, p53, and prognosis in cervical cancers.

Haensgen G, Krause U, Becker A, Stadler P, Lautenschlaeger C, Wohlrab W, Rath FW, Molls M, Dunst J.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):865-72.

PMID:
11429213
7.

Expression of cIAP1, a target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy.

Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, Hirohashi S, Inazawa J.

Cancer Res. 2002 Sep 1;62(17):4860-6.

8.

Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer.

Nakamura K, Abarzua F, Hongo A, Kodama J, Nasu Y, Kumon H, Hiramatsu Y.

Ann Oncol. 2009 Jan;20(1):63-70. doi: 10.1093/annonc/mdn556. Epub 2008 Aug 9.

9.

Clinicopathological and prognostic significance of Bmi-1 expression in human cervical cancer.

Min L, Dong-Xiang S, Xiao-Tong G, Ting G, Xiao-Dong C.

Acta Obstet Gynecol Scand. 2011 Jul;90(7):737-45. doi: 10.1111/j.1600-0412.2011.01102.x. Epub 2011 Mar 29.

PMID:
21309753
10.

Frequent loss of tumor suppressor ARID1A protein expression in adenocarcinomas/adenosquamous carcinomas of the uterine cervix.

Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Ishikawa M, Ishibashi T, Iida K, Otsuki Y, Nakayama S, Miyazaki K.

Int J Gynecol Cancer. 2012 Feb;22(2):208-12. doi: 10.1097/IGC.0b013e3182313d78.

PMID:
22274316
11.

Overexpression of Bmi-1 in uterine cervical cancer: correlation with clinicopathology and prognosis.

Zhang X, Wang CX, Zhu CB, Zhang J, Kan SF, Du LT, Li W, Wang LL, Wang S.

Int J Gynecol Cancer. 2010 Dec;20(9):1597-603.

PMID:
21370603
12.

Interstitial fluid pressure as a prognostic factor in cervical cancer following radiation therapy.

Yeo SG, Kim JS, Cho MJ, Kim KH, Kim JS.

Clin Cancer Res. 2009 Oct 1;15(19):6201-7. doi: 10.1158/1078-0432.CCR-09-0560. Epub 2009 Sep 22.

13.

Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions.

Davidson B, Berner A, Trope' CG, Wang TL, Shih IeM.

Hum Pathol. 2007 Jul;38(7):1030-6. Epub 2007 Mar 27.

PMID:
17391728
14.

Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival.

Hazelbag S, Kenter GG, Gorter A, Dreef EJ, Koopman LA, Violette SM, Weinreb PH, Fleuren GJ.

J Pathol. 2007 Jul;212(3):316-24.

PMID:
17503414
15.

No relationship is indicated between FHIT expression and clinicopathologic prognostic parameters in early stage cervical carcinoma.

Baykal C, Ayhan A, Al A, YĆ¼ce K, Ayhan A.

Int J Gynecol Cancer. 2003 Mar-Apr;13(2):192-6.

PMID:
12657123
16.

[The expression of c-myc protein in uterine cervical cancer: a possible prognostic indicator].

Wu HJ.

Nihon Sanka Fujinka Gakkai Zasshi. 1996 Jul;48(7):515-21. Japanese.

PMID:
8754393
17.

Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix.

Kim YB, Kim GE, Pyo HR, Cho NH, Keum KC, Lee CG, Seong J, Suh CO, Park TK.

Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):822-9.

PMID:
15465199
18.

Biological role and prognostic significance of NAC1 in ovarian cancer.

Nakayama K, Rahman MT, Rahman M, Yeasmin S, Ishikawa M, Katagiri A, Iida K, Nakayama N, Miyazaki K.

Gynecol Oncol. 2010 Dec;119(3):469-78. doi: 10.1016/j.ygyno.2010.08.031. Epub 2010 Sep 24.

PMID:
20869761
19.

Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.

Watari H, Ohta Y, Hassan MK, Xiong Y, Tanaka S, Sakuragi N.

Gynecol Oncol. 2008 Mar;108(3):527-32. doi: 10.1016/j.ygyno.2007.11.026. Epub 2008 Jan 4.

PMID:
18177691
20.

Bcl-2 expression in preinvasive and invasive cervical lesions.

Ozalp SS, Yalcin OT, Tanir HM, Dundar E, Yildirim S.

Eur J Gynaecol Oncol. 2002;23(5):419-22.

PMID:
12440815
Items per page

Supplemental Content

Write to the Help Desk